Antiphospholipid syndrome (APS) is an autoimmune disorder characterised by the persistent presence of antiphospholipid antibodies (aPL), which significantly increase the risk of thrombosis and adverse ...

Patients with thrombotic antiphospholipid syndrome are better treated with a vitamin K antagonist, such as warfarin, rather than a direct oral anticoagulant (DOAC), a new systematic review and ...

Targeting glycolysis can help lower neutrophil extracellular trap formation in antiphospholipid syndrome. Neutrophils are an important type of white blood cell that help your immune system fight ...

The primary manifestation of the antiphospholipid antibody syndrome (APS) is thrombosis, which forms the core of the classification criteria for this syndrome. However, multiple other noncriteria ...

Please provide your email address to receive an email when new articles are posted on . Preventing a first clotting event with aspirin may be the only truly effective treatment option in ...

Investigators from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) presented new research findings in antiphospholipid syndrome (APS) at the ...

Each year, around two of every 100,000 American adults receive a new diagnosis of antiphospholipid syndrome, or APS, an autoimmune disease known to cause inflammation and recurring, potentially fatal, ...

Asherson’s syndrome, also known as catastrophic antiphospholipid syndrome (CAPS), is an extremely rare autoimmune condition. It is defined by the fast progression of blood clots impacting many organ ...

APS is a systemic autoimmune disease associated with persistent antiphospholipid antibodies (aPL). It can cause thrombosis and pregnancy complications as well as non-thrombotic manifestations such as ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “Do COVID-19 patients get blood clots? Yes, they do,” Yu ...

Scientists have discovered that 'rogue' antibodies found circulating in the blood of COVID-19 patients have the potential to cause endothelial cells to lose their resistance to clotting. These ...